We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Early outcomes of Basiliximab administration before and after lung allograft reperfusion.
- Authors
Costello, John P.; Rodrigues, Adrian; Curran, Brett; Schwartz, Jeffrey; Dilling, Daniel; Bakhos, Mamdouh; Jeske, Walter; Walenga, Janine; Vigneswaran, Wickii T.
- Abstract
Background: The use of Basiliximab as an induction immunosuppression agent in lung transplantation is well-established and is associated with a decreased incidence of acute rejection and improved survival. However, variation exists in the timing of administration of Basiliximab with regard to reperfusion of the lung allograft. Methods: Serum blood samples were obtained from 30 patients undergoing lung transplantation at a single lung transplantation center between February 2017 and January 2018. The samples were evaluated for 12 different cytokines, including IL-2. Primary graft dysfunction (PGD) scores were calculated at four time points in the first 72 hours following surgery. These cytokine levels and PGD scores were then compared with regard to when Basiliximab was administered. Results: 20 patients received induction immunosuppression with Basiliximab (7 patients before reperfusion, 13 patients after reperfusion). Cytokine levels were not different between the groups. Patients administered Basiliximab after reperfusion had significantly lower PGD scores immediately and at 24 hours postoperatively compared to patients receiving Basiliximab before reperfusion (differences in mean PGD scores p<0.001 and p=0.004, respectively). Patients administered Basiliximab prior to reperfusion had a statistically significant reduction in mean PGD scores over the first 72 hours postoperatively (p=0.045). Conclusion: When Basiliximab was administered before allograft reperfusion in lung transplantation, initial PGD scores were higher, but there was a statistically significant progressive reduction in postoperative PGD scores over the first 72 hours following allograft implantation. There were no significant differences in the rates of acute rejection or infection at 6 months regardless of Basiliximab administration timing.
- Subjects
BASILIXIMAB; REPERFUSION; LUNG transplantation; SERUM; LUNGS; IMMUNOSUPPRESSION
- Publication
Trends in Transplantation, 2019, Vol 12, Issue 2, p1
- ISSN
1887-455X
- Publication type
Article
- DOI
10.15761/TiT.1000265